133 related articles for article (PubMed ID: 35842123)
1. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
Dheyriat L; Ward D; Beaugerie L; Jess T; Kirchgesner J
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):164-172.e11. PubMed ID: 35842123
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
[TBL] [Abstract][Full Text] [Related]
3. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
Biron A; Beaugerie L; Chazouillères O; Kirchgesner J
Aliment Pharmacol Ther; 2022 Sep; 56(5):857-868. PubMed ID: 35789494
[TBL] [Abstract][Full Text] [Related]
4. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
5. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
6. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
7. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
8. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
11. Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: a nationwide cohort study.
Friedman S; Garvik OS; Nielsen J; Nørgård BM
Aliment Pharmacol Ther; 2022 Sep; 56(5):823-830. PubMed ID: 35770457
[TBL] [Abstract][Full Text] [Related]
12. Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study.
Charkaoui M; Hajage D; Tubach F; Beaugerie L; Kirchgesner J
J Crohns Colitis; 2022 Jul; 16(6):893-899. PubMed ID: 34657962
[TBL] [Abstract][Full Text] [Related]
13. Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.
Meyer A; Taine M; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1269-1281.e9. PubMed ID: 34298191
[TBL] [Abstract][Full Text] [Related]
14. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
15. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
[TBL] [Abstract][Full Text] [Related]
16. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Aliment Pharmacol Ther; 2013 Feb; 37(4):420-9. PubMed ID: 23240738
[TBL] [Abstract][Full Text] [Related]
18. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Vedamurthy A; Gangasani N; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
[TBL] [Abstract][Full Text] [Related]
20. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
Ward D; Nyboe Andersen N; Gørtz S; Thorn Iversen A; Højgaard Allin K; Beaugerie L; Kirchgesner J; Jess T
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):135-143.e8. PubMed ID: 37442315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
